Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Amylyx says it will present Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia in a late-breaking oral session set for Nov. 15, 2026, in Washington, D.C., after prior disclosed positive topline results.
Amylyx Pharmaceuticals will present topline data from its Phase 3 LUCIDITY clinical trial of avexitide, an investigational treatment for post-bariatric hypoglycemia, at the ObesityWeek® 2026 Annual Meeting. The trial met its primary efficacy endpoint.
Amylyx Pharmaceuticals announced it will present topline results from its Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia at the ObesityWeek® 2026 Annual Meeting.